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This study investigated whether NGF prevents tumor growth by promoting neuronal regulation of tumor
blood flow. HT1080 fibrosarcoma cells or HepG2 hepatitis cells were subcutaneously implanted into nude
mice. On Day 21 after the implantation of tumor cells, human NGF (40 or 80 ng/h for 14 days) was
administered using a micro-osmotic pump. Growth rates of both tumors were significantly inhibited by
the treatment of NGF, and the survival rate was also extended. Significant suppression of HT1080 tumor
growth lasted after withdrawing NGF. NGF markedly increased the density of a-smooth muscle actin (a-
SMA)-immunoreactive (ir) cells without changing neovessel density in HT1080 tumor tissues. Double
immunostaining demonstrated protein gene product (PGP) 9.5-ir nerves around a-SMA-ir cells were
found in HT1080 tumor tissue treated with NGF. The blood flow in HepG2 tumors treated with saline was
significantly higher than in the non-tumor control area, but the tumor blood flow was markedly reduced
by NGF treatment. In in vitro studies, NGF significantly accelerated migration of aortic smooth muscle
cells but not endothelial cells, whereas NGF had no cytotoxic action on both cells. NGF inhibits tumor
growth via indirect action, probably through innervation and maturation of tumor neovasculature, which
regulates blood flow into tumor tissues.
© 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The growth of tumor cells mainly depend on angiogenesis, or
new blood vessel formation to produce blood flow into tumor
tissues.1e3 It is generally accepted that the local blood flow in
normal tissues is regulated by the maintenance of vascular tone via
perivascular nerves innervating terminal arterioles, precapillary
arterioles, and the endothelium.4e6 We have reported that theIR, immunoreactive; NANC,
tor; PBS, phosphate-buffered
, Protein Gene Product 9.5.
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d/4.0/).neovasculature in tumor tissues has no perivascular innervation.7
Moreover, the perivascular innervation of the tumor has been
shown to disappear progressively from the edge of the tumor when
tumor growth advances.8 The neovasculature in tumor tissues has
been reported to consist of endothelium-like and immature vessels
without a coating of smooth muscle cells.7,8 Therefore, it is ex-
pected that lack of the neuronal regulation in tumor vasculatures
may produce a sufficient blood supply into tumor tissues, thereby
accelerating proliferation and growth.
Nerve growth factor (NGF) is essential for the development and
innervation of peripheral nerves.9 Our previous report demon-
strated that NGF innervates perivascular nerves into the neo-
vasculature of the mouse cornea, which were derived by basic
fibroblast growth factor (bFGF),10 as well as tumor cells, including
DU145 prostate and HT1080 fibrosarcoma cells.7 Furthermore, wenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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vascular adrenergic nerves and nonadrenergic noncholinergic
(NANC) nerves in rat small mesenteric arteries, which were injured
by topical application of phenol onto the superior mesenteric ar-
tery.11 Moreover, we demonstrated that NGF suppressed the
growth of DU145 cells by increasing the number of vascular smooth
muscle cells of the neovasculature in nude mice, suggesting that
NGF facilitates the innervation of perivascular nerves and matures
the neovasculature in tumor tissues.12 NGF may have suppressive
effects on tumor growth by facilitating innervation in the neo-
vasculature in tumor tissues. However, we could not exhibit evi-
dence for perivascular innervation of neovessels in tumor area after
NGF therapy and anti-tumor effects of NGF on tumor types other
than DU145 cells.
Therefore, the present study further investigated whether NGF
has anti-tumor effects on the growth of HT1080 and HepG2 hep-
atitis tumor cells. Additionally, the aim of the present study was to
determine whether the effects of NGF are involved in the inner-
vation of perivascular nerves to regulate blood flow into tumor
tissues.2. Materials and methods
2.1. Animals
Five-week-old BALB/c Slc nu/nu mice (purchased from Shimizu
Experimental Animals, Shizuoka, Japan) were used in this study.
This study was performed in accordance with the Guidelines for
Animal Experiments at Okayama University Advanced Science
Research Center, Japanese Government Animal Protection and
Management Law No. 115 and Japanese Government Notification
on Feeding and Safekeeping of Animals No. 6. Every effort was
made to minimize the number of animals used and their pain.2.2. Implantation of tumor cells into nude mice
Implantation of human fibrosarcoma HT1080 cells and human
hepatitis HepG2 cells obtained from American Type Culture
Collection (ATCC, Rockville, MD, USA), was carried out according to
a previous report.12 All cells were cultured in RPMI 1640 medium
supplemented with 10% heat-inactivated FBS (SIGMA, Tokyo,
Japan), 100 U/mL penicillin, and 100 mg/mL streptomycin. Each cell
(1  106 cell/50 mL) mixed with 50 mL of Matrigel was injected into
the flanks of nude mice (100 mL/site).2.3. NGF administration
On Day 21 after the implantation of tumor cells, a micro-
osmotic pump (DURECT Corp., Cupertino, CA, USA) containing
human NGF (Toyobo Co., Osaka, Japan) or sterile saline was sub-
cutaneously implanted in the dorsal area of mice. NGF (40 or
80 ng/h) was administered for 14 days. The osmotic pump was
surgically removed under ether anesthesia after a 2-weeks
administration of NGF.2.4. Measurement of tumor volumes
Tumor growth was determined by measuring the size of tumors
from Day 7 to Day 56 after the implantation of each tumor cell.
Tumor volumes were calculated according to the formula
(width2  length)/2.2.5. Immunohistochemistry
The immunohistochemical study on the neovasculature of tu-
mor tissues was carried out according to previous reports.7,12 On
Day 35 after the saline or NGF treatment for 2 weeks, nude mice
were anesthetized with pentobarbital-Na (50 mg/kg, i.p.) and
sacrificed by bleeding. Thereafter, Zamboni solution (2% para-
formaldehyde and 15% picric acid in 0.15 M phosphate buffer) was
systemically perfused via the heart, and tumor tissues were
immersion-fixed with Zamboni solution for 48 h. Five areas at the
tumor periphery that contained the maximum number of discrete
microvessels were identified. The density of vessels in each field
was expressed as vessels per field.
To examine the effects of NGF on smooth muscle cell prolifer-
ation, dehydrated and paraffined tumor tissues were sliced in 7-mm
thick sections, which were incubated in Cy3-labeled anti-a-SMA
mouse IgG (SIGMA, Tokyo, Japan) at 1:100 dilution for 1 h at room
temperature and observed under a confocal laser scanning micro-
scope (CLSM510, Carl Zeiss, Tokyo, Japan). The densities of neo-
vessels and vascular smooth muscle in tumor tissues were
determined using the imaging analyzer Simple PCI (View Sonic,
Complex Inc., Imaging Systems, Cranbery Township, USA).
To observe perivascular innervation with double immuno-
staining, the tissues were treated with 30% KHOH solution at 60 C
for 7 min. After fixation, each tissue was rinsed with PBS, immersed
in 1% SDS plus 0.5% Triton-X/PBS for 48 h, and then incubated with
PBS containing normal goat serum (Gibco-BRL, Gaithersburg, MD,
USA) (1: 100) for 60 min. The tissues were incubated with the
primary antibody of rabbit polyclonal anti-PGP 9.5 serum (1: 100)
(Neo markers, Fremont, CA, USA) at 4 C for 72 h. After the incu-
bation, the tissues were washed in PBS and incubated with the
secondary antibody of FITC-labeled goat anti-rabbit IgG (1: 100)
(ICN Pharmaceuticals, Inc., Aurora, OH, USA) for PGP 9.5 or mono-
clonal anti-a-SMA Cy3-conjugated mouse IgG (1:400) (SIGMA,
Tokyo, Japan) for vascular smooth muscle at 4 C for 60 min. The
samples were washed in PBS, mounted on slides, cover-slipped
with glycerol/PBS (2: 1 v/v), and observed under a confocal laser-
scanning microscope (CLSM510, Carl Zeiss GmbH, Jena, Germany).
Double immunostaining of perivascular nerves (PGP 9.5-ir) and
vascular smooth muscle (a-SMA-ir) was performed in two fluo-
rescence views in the same microscopic field.
2.6. Measurement of tumor blood flow
On Day 35 after the saline or NGF treatment for 2 weeks, the
nude mice were anesthetized with pentobarbital-Na (50 mg/kg,
i.p.). The blood flow of the flank surface in the HepG2 tumor and
normal (non-tumor) area of the nude mouse was measured with a
blood flow meter probe (OMEGAFLO FLO-C1, Omegawave Inc.,
Tokyo, Japan). The blood flow for one minute was repeated 3 times
and the average of 3 times was calculated with following the for-
mula; relative blood flow (%) ¼ the average blood flow of tumor
area/the average blood flow of normal area. The blood flow of the
same area in the nude mouse without tumor implantation was
taken as the control.
2.7. Cell migration assay
2.7.1. Primary culture
Primary mouse smooth muscle cell and endothelial cell cultures
were established according to a modification of a previous report.13
The BALB/c Slc mouse descending aortas were de-endothelialized
via passage of an applicator. Aortic tissue was minced and frag-
ments were put in Dulbecco's Modified Eagle's Medium (DMEM,
Life Technologies, Inc. Tokyo, Japan) with 0.1% collagenase type II
Fig. 1. Time-course changes in tumor volume (A) and survival rate (B) during
administration (c, e) and discontinuation (d, f) of nerve growth factor (NGF; 40 ng/h) in
nude mice implanted with HT1080 fibrosarcoma cancer cells. NGF or saline was
administered from Day 21 to Day 35 with an osmotic pump. In (A), tumor volumes
were calculated according to the formula (width2  length)/2. Each bar indicates the
mean ± S.E.M. *P < 0.05 vs. Saline (Tukey's test). In (B), survival rate was expressed as
the percentage of mice with adequate tumor control (<3000 mm3) in each group.
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and 0.2 mM L-ascorbic acid (SIGMA, Tokyo, Japan) for 12 h at room
temperature. The dispersed cells were filtered through 70-mm
monofilament nylon mesh. The filtered cell suspension was
centrifuged at 1000 rpm at 4 C for 5 min. The pellet was collected
and washed using DMEM. Then, primary smooth muscle cells were
cultured in 6 well culture plates (Life Technologies, Inc. Tokyo,
Japan) with DMEM supplemented with 10% FBS, 1% (v/v) penicillin-
streptomycin (SIGMA, Tokyo, Japan), and 0.2 mM L-ascorbic acid.
To obtain endothelial cells, the C57BL/6 Slc mouse descending
aorta was aseptically harvested. Aortic tissue was minced and
fragments were incubated (37 C, 5% CO2) on Matrigel-coated 6
well culture plates in Humedia-EB2 medium (Kurabo Co., Osaka,
Japan) with 2% FBS, endothelial cell growth supplements (10 ng/mL
epidermal growth factor, 3 ng/mL basic fibroblast growth factor,
1 mg/mL hydrocortisone, 10 mg/mL heparin salt), 50 mL/mL genta-
mycin, and 50 ng/mL amphotericin B) for seven days. Then, primary
endothelial cells were cultured on gelatin-coated 6 well culture
plates with supplemented Humedia-EB2 medium. Smooth muscle
cells and endothelial cells were grown to 80% or greater confluence
and were passaged with trypsin before being used in experiments.
Only cells between passages 2 and 6 were used.
2.7.2. Assays for cell migration
The migration of endothelial cells was assayed as described pre-
viously.13,14 In brief, confluent cells in 48 well plates were scratched
with a sterile pipette tip. The cellswerewashed twicewith Humedia-
EB2medium to remove cellular debris. Then, 300 mL of Humedia-EB2
medium with 0.5% FBS and NGF (10 and 50 ng/mL or PDGF (10 ng/
mL) was added to each well. The endothelial cells were then incu-
bated at 37 C in 5% CO2 for 24 h. The cell migration assays were also
performed for smooth muscle cells using the same method as
described above. After 24-h culture, the cells were fixed with 2% PFA.
The cells that had migrated into the denuded area were photo-
graphed with a CCD camera and counted with Image J software.
2.8. Measurement of tumor cell viability
HT1080 or HepG2 cells (100 mL; 1  104 cells) in the logarithmic
growth phase were cultured on a 96-well plate for 24 h and incu-
bated with NGF solution (5e500 ng/mL) or saline for an additional
24 h or 48 h. After adding 10 mL of the working solution from the
WST-8 kit (Kishida Chemical., Ltd, Osaka, Japan.), the absorbance
was measured at 450 nm with a reference wavelength at 650 nm
with the microplate reader (BioRad, Hercules, CA, USA).
2.9. Statistic analysis
All data are expressed as the mean ± S.E.M. Statistical analysis
was performed using unpaired Student's t-tests or ANOVA followed
by Tukey's test or Dunnet's test. P-values <0.05 were considered
significant.
3. Results
3.1. Time-course changes in HT1080 tumor volume during
administration and after the discontinuation of NGF
Measurable HT1080 cells developed within 14 days after the im-
plantation. As shown in Fig. 1A, tumor volumes in the saline-treated
group rapidly increased, and all mice treated with saline were sacri-
ficedonDay42.Oncontrary, the tumorvolumes inNGF-treatedgroup
gradually increased during the administration, andwere significantly
smaller than those in saline group (Fig. 1A). Furthermore, the tumor
growth inhibition in NGF-treated group was maintained even afterthe discontinuation of NGF administration (Fig. 1d). The tumor vol-
umes after NGF discontinuationwere significantly smaller than those
in saline-treated group until Day 42 (Fig. 1d).
The survival rate, which was expressed as the percentage of
mice with adequate tumor volume less than 3000 mm3, rapidly
decreased by 50% on Day 35 in the saline-treated group and
reached zero on Day 42 (Fig. 1B). However, NGF administration
(40 ng/h) for 2 weeks maintained a 100% survival rate on Day
35 (Fig. 1e). Furthermore, a survival rate higher than 50% lasted
until Day 56 after NGF discontinuation (Fig. 1f).3.2. Effects of NGF on density of neovessels and smooth muscle in
HT1080 tumor tissues
Tumors removed from animals administered saline and NGF
had a high density of vessels, but no difference, indicating the
presence of extensive angiogenesis in the tumors (Fig. 2A, B, E).
NGF treatment significantly demonstrated greater a-SMA-
immunoreactive (ir) cells in the tumors than with saline treat-
ment (Fig. 2C, D, F).
Fig. 2. Effects of nerve growth factor (NGF; 40 ng/h) on tumor angiogenesis in nude mice implanted with HT1080 cells. In the upper left panel, representative light micrographs
show microvessels (open triangles) in tumors from animals that received saline (A) or NGF (B). A bar graph (E) shows quantitative analysis of microvessel density by counting the
positively stained cells in five different fields (  200). In the upper right panel, representative fluorescence micrographs show a-smooth muscle actin (a-SMA)-immunoreactive
microvessels in tumors from animals that received saline (C) or NGF (D). A bar graph (F) shows quantitative analysis of vascular smooth muscle density by computer-assisted image
processing in five different fields (  200). Each bar indicates the mean ± S.E.M. *P < 0.05 vs. Saline (Student's t-test).
Fig. 3. Representative confocal laser micrographic images showing the distribution of protein gene product (PGP) 9.5-immunoreactive (ir) nerves (green) and a-smooth muscle
actin (a-SMA)-ir neovessels (red) in the HT1080 tumor tissue of nude mice treated with saline (A) or NGF (40 ng/h) (B, C, D). White arrows indicate perivascular nerves in close
contact with smooth muscles (yellow). Scale bars indicate 50 (A, B) and 20 (C, D) mm.
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Fig. 4. Time-course changes in tumor volume (A) and survival rate (B) during
administration of nerve growth factor (NGF; 40 and 80 ng/h) and saline in nude mice
implanted with HepG2 hepatitis cancer cells. NGF or saline was administered from Day
21 to Day 35 with an osmotic pump. In (A), tumor volumes were calculated according
to the formula (width2  length)/2. Each bar indicates the mean ± S.E.M. *P < 0.05,
**P < 0.01 vs. Saline (Dunnet's test). In (B), survival rate was expressed as the per-
centage of mice with adequate tumor control (<800 mm3) in each group.
Fig. 5. Effects of nerve growth factor (NGF; 40 and 80 ng/h) on blood flow in tumor
tissues of nude mice implanted with HepG2 hepatitis cancer cells. Relative blood flow
was expressed as the average blood flow of tumor area/the average blood flow of
normal area. *P < 0.05 vs. control (Dunnet's test). #P < 0.05 vs Saline (Dunnet's test).
(n); number of mice.
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Double immunostaining of a-SMA- and PGP 9.5-ir cells revealed
that the HT1080 tumor tissues treated with saline had no PGP 9.5-ir
cells (Fig. 3A). However, the HT1080 tumor tissues treatedwith NGF
exhibited many PGP 9.5-ir cells, most of which were in close con-
tact with a-SMA-ir neovessels (Fig. 3B, C, D).
3.4. Time-course changes in HepG2 tumor volume after NGF
administration
Measurable HepG2 tumor cells developed within 14 days after
the implantation. NGF administration at 40 and 80 ng/h for 14 days
dose-dependently inhibited increases in tumor volumes (Fig. 4A).
In particular, there was significant difference in tumor volume be-
tween the NGF (80 ng/h)- and saline-treated groups.
The survival rate, whichwas expressed as the percentage ofmice
with adequate tumor volume less than 800 mm3, was decreased by
approximately 40% on Day 35 in the saline-treated group (Fig. 4B).
However, NGF administration dose-dependently maintained an
approximately 70e100% survival rate on Day 35 (Fig. 4B).
3.5. Effects of NGF on blood flow in HepG2 tumor tissues
The blood flow in HepG2 tumor tissue was significantly higher
than that in non-tumor tissue (Fig. 5). The NGF treatment canceled
the increased blood flow in HepG2 tumor tissue, and significantly
reduced it to the control level (Fig. 5).
3.6. Effects of NGF on migration of endothelial and smooth muscle
cells
The control group showed no migration of endothelial and
smooth muscle cells (Fig. 6A, B). PDGF, but NGF, had significant
effect on the migration of endothelial cells (Fig. 6A). NGF (only
10 ng/mL) or PDGF significantly accelerated the migration of
smooth muscle cells (Fig. 6B).
3.7. Effects of NGF on viability of HT1080 and HepG2 tumor cells
The treatment with NGF (5e500 ng/mL) for 48 h had no effect
on the viability of HT1080 (Fig. 7A) or HepG2 cells (Fig. 7B).
4. Discussion
The present study demonstrated a first evidence that NGF
significantly inhibits tumor growth of HT1080 fibrosarcoma cells
and HepG2 liver cancer cells implanted into nude mice, which is
mediated by increasing SMA density in tumor neovessels with
newly distribution of perivascular nerves followed by a significant
decreased blood flow in tumor tissues, resulting in prolonged the
survival rate in vivo. The present findings are in good accordance
with the previous study in which NGF inhibited growth of DU145
human prostate cancer cells implanted into nude mice.12 Further-
more, the inhibitory effects of NGF on HT1080 tumor growth was
maintained even after the discontinuation of NGF, suggesting that
NGF causes the tumor growth inhibition by an indirect effect,
probably changing environment around the tumor. This notion is
supported by the present and previous findings that NGF had no
direct effects on viability of HT1080, HepG2, and DU145 prostate
cancer cells.12 Our previous studies revealed that NGFhas no or little
effect on the development of angiogenesis derived from HT1080 or
DU145 tumor cells implanted into the mouse cornea7 or DU145
prostate cancer cells implanted into thenudemouse.12 Furthermore,
these findings were confirmed by the present study in which NGF
H. Kawasaki et al. / Journal of Pharmacological Sciences 140 (2019) 1e76did not accelerate neovessel formation in HT1080 tumors in nude
mice in vivo and had no significant effects on migration of endo-
thelial cells in vitro. Thus, it appears that NGF does not promote
angiogenesis under pathological conditions such as tumors.
The neovessels in tumor tissues are mainly constituted from an
endothelium without a cover of vascular smooth muscle cells and
become frangible blood vessels.15 Our previous study demonstrated
that severe bleeding and/or blood leakage appeared in the HT1080
and DU145 tumor area of the mouse cornea, suggesting that
DU145- and HT1080-derived neovessels are immature and fragile
vessels with less vascular smooth muscle.7
On the other hand, in the present study, it should be noted that
NGF-treated HT1080 tumor tissues had amarked increase in a-SMA
immunoreactive (ir) cells. NGF has been reported to enhance
migration of human lung fibroblasts as well as human vascular
smooth muscle cells.16,17 Furthermore, our previous studies
demonstrated that NGF caused a significant increase in a-SMA-ir
cells in the mouse cornea implanted with HT1080 or DU145 cells,
and in the DU145 tumors in nude mice.7,12 These effects of NGF
were supported by the present study in which NGF significantly
enhanced the migration of smooth muscle cells, similar with PDGF.Fig. 6. Effects of nerve growth factor (NGF; 10 and 50 ng/mL) and platelet-derived growth fa
cells (B) in vitro. Each bar indicates the mean ± S.E.M. *P < 0.05 vs. Saline (Dunnet's test).
Fig. 7. Effects of nerve growth factor (NGF) on viability of HT1080 (A) and HepG2 (B) can
indicates the mean ± S.E.M. (n); number of samples.This effect of NGF on the migration appeared to be specific to
smooth muscle cells because NGF had no effect on endothelium
migration, whereas PDGF accelerated the migration of both cell
types. Taken together, it is strongly suggested that NGF facilitates
the migration of vascular smooth muscle cells to tumor neovessels,
directly or indirectly, probably via perivascular nerves. Further-
more, it seems likely that NGF accelerates the maturation of tumor
neovessels by smooth muscle cell migration, and leads to regula-
tion of blood flow toward the tumor tissues, resulting in the sig-
nificant suppression of tumor growth. As the peripheral nerves
provide a template that determines the organotypic pattern of
blood vessel branching and arterial differentiation in the skin.18 it is
highly possible that the migration of smooth muscles and matu-
ration of neovessels resulted from perivascular innervation by NGF.
In thepresentdouble immunostaining studyusing theneuroaxonal
marker PGP 9.5 and smooth muscle marker a-SMA, PGP9.5-ir nerves
were not observed in theHT1080 tumor tissue treatedwith saline. This
result is supported by the previous findings that blood vessels and
neovessels within tumor tissues lacked a neuronal apparatus,19 and
PGP9.5-ir nerves in the HT1080 tumor area of the mouse corneawere
sparse and distant from a-SMA-ir neovessels and were not in contactctor (PDGF; 10 ng/mL) on the migration of primary endothelial (A) and smooth muscle
(n); number of samples.
cer cells. The viability was assayed by the WST-8 reduction method in vitro. Each bar
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vesselshad fewer, if any,perivascularnerves. The reason for the lackof a
nervous system in tumor vessels may be that tumor tissues produce
and release inhibitory substances, such as semaphorin 3A, which pre-
vent the distribution of perivascular nerves.20e22
The present study also demonstrated that PGP9.5-ir nerves
appeared in HT1080 tumor tissue after the treatment with NGF but
notwith saline, and theywere in close contactwith and accompanied
a-SMA-ir neovessels, suggesting that NGF facilitates the innervation
of perivascular nerves into neovessels in the tumor. Our previous
studies have confirmed that perivascular nerves, which were re-
innervated by the treatment with NGF following phenol-induced
nerve injury in the rat mesenteric artery, have an active function to
regulate vascular responses and blood flow.11 Additionally, NGF pro-
nouncedly increased a SMC recruitment, and also facilitated the
innervation of perivascular nerves, resulting in decreasing blood flow
toward the tumor neovessels via neural regulation, as shown our
previous reports.7 The peripheral nerves determine the blood vessel
branching and arterial differentiation in the skin,18 and enhanced
blood vessel maturation inhibits tumor growth without suppressing
angiogenesis. Moreover, no bleeding and/or blood leakage from
DU145 or HT1080 tumor tissues in the mouse cornea appeared after
treatment with NGF, contrary to with saline treatment.7 Taken
together, it is likely that NGF develops neovessels derived from
HT1080andHepG2cells intomatureandstablevessels. Therefore, it is
strongly suggested that NGF facilitates the maturation of tumor
neovessels by smooth muscle cell migration via the innervation of
perivascular nerves, which may regulate the blood flow toward the
tumor tissues, and result in the suppression of tumor growth. This
notion is supported by the present findings that the increased blood
flow in the HepG2 tumor was prominently cancelled to the control
level by NGF treatment. Since the neovessels in tumor tissue were
frangible and easy to cause bleeding, the hypoxia levels in tumor area
have been reported to be relatively higher than normal area and
thereby increase angiogenesis, which induces the increased blood
flow in the tumor area.23 Therefore, it is likely that the maturation of
neovessels byNGFmaintains and normalizes the bloodflow to tumor
tissue and reduces the hypoxia levels in tumor area, which inhibits
angiogenesis and proliferation of tumor cells.
The present study employed human NGF, because of the treat-
ment of human tumor cells implanted into the nudemouse, and the
report that mouse NGF have no effects on the proliferation of TF1
cell with human receptor TrkA.24 Paoletti and colleagues also re-
ported that human NGF and mouse NGF have a high degree (ca.
90%) of sequence identity.24 Although it is unknown whether hu-
man NGF could bind to mouse NGF receptor (TrkA) to promote
perivascular innervation of neovessels, it has widely assumed that
the two proteins are functionally interchangeable, that is, human
NGF is likely to act on mouse TrkA. Additionally, we have reported
that human NGF has function of innervation in mouse neo-
vessels10,25 and re-innervation of rat perivascular nerves injured by
phenol.11 These studies strongly indicate that human NGF could
bind mouse and rat TrkA to promote perivascular innervation.
In conclusion, the present results suggest that NGF facilitates the
innervation of perivascular nerves in order to mature neovessels and
regulate blood flow toward the tumor tissues. NGF may suppress tu-
mor growth by accelerating the maturation of neovasculatures and
innervation of perivascular nerves in tumor tissues. Additionally, in
the preliminary study, combination of NGF with an anti-vascular
endothelial growth factor (VEGF) drug, bevacizumab, enhanced
further inhibitory effect of NGF alone on HepG2 tumor growth. We
expect that NGF, through perivascular innervation, stabilizes and
matures the neovessels, which remained after anti-VEGF therapy. It is
suggested that NGF and/or combined anti-cancer drugwith NGFmay
have the potential to be a novel anticancer therapy.Conflict of interest
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